News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

San Diego's Pfenex Inc. Files For A $75 Million IPO To Fund Development Of Wet AMD Drug



6/6/2014 6:35:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfenex, a biotech developing an alternative to Roche's Lucentis treatment for wet AMD, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. Lucentis generates over $4.3 billion annually for Roche, which manufactures and sells the drug in the U.S., and Novartis ( NVS ), which markets it outside the country. Pfenex is also developing candidates for other high-value protein therapeutics.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES